8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Jan 2, 2026·SEC
Eledon Pharmaceuticals, Inc.(ELDN)Earnings, Financials & Key Ratios
ELDN•NASDAQ
Price updated Jun 19, 2026
AboutEledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Show more
- Revenue$0
- EBITDA-$83M-18.1%
- Net Income-$46M-26.1%
- EPS (Diluted)-0.56+25.3%
- ROE-45.79%+20.7%
ELDN Key Insights
Eledon Pharmaceuticals, Inc. (ELDN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 92 (top 8%)
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Profits declining 14.9% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 68.6% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ELDN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ELDN Price & Volume
Eledon Pharmaceuticals, Inc. (ELDN) stock price & volume — 10-year historical chart
Loading chart...
ELDN Growth Metrics
Eledon Pharmaceuticals, Inc. (ELDN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-310.26%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM60.71%
Return on Capital
10 Years-61.06%
5 Years-49.9%
3 Years-53%
Last Year-52.61%
ELDN Recent Earnings
Eledon Pharmaceuticals, Inc. (ELDN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.16+27.3%
$0.22
Rev
—
—
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.10+50.0%
$0.20
Rev
—
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.21+4.5%
$0.22
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.13+43.5%
$0.23
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.16vs $0.22+27.3% | — |
| Q2 2026 | Mar 19, 2026 | $0.10vs $0.20+50.0% | — |
| Q4 2025 | Nov 14, 2025 | $0.21vs $0.22+4.5% | — |
| Q3 2025 | Aug 14, 2025 | $0.13vs $0.23+43.5% | — |
Based on last 12 quarters of dataView full earnings history →
ELDN Peer Comparison
Eledon Pharmaceuticals, Inc. (ELDN) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 AGIO | 2.03B | 34.16 | -4.80 | 48.03% | -6.4% | -34.11% | 0.05 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% |
Compare ELDN vs Peers
Eledon Pharmaceuticals, Inc. (ELDN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ELDN Income Statement
Eledon Pharmaceuticals, Inc. (ELDN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 22K | 11K | 182K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -22K▲ 0% | -11K▲ 50.0% | -182K▼ 1554.5% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | 37.14% | 50% | -1554.55% | 100% | - | - | - | - | - | - |
Operating Expenses | 13.12M | 14.06M | 14M | 18.46M | 36.87M | 88.43M | 43M | 70.58M | 83.25M | 86.47M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 11.1M | 7.24M | 5.87M | 10.05M | 13.13M | 12.7M | 12.69M | 18.61M | 16.98M | 16.54M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 2.02M | 6.82M | 8.13M | 6.13M | 23.73M | 27.08M | 30.31M | 51.96M | 66.27M | 69.93M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 5K | -5K | 0 | 2.28M | 0 | 48.65M | 0 | 0 | 0 | 0 |
Operating Income | -13.12M▲ 0% | -14.06M▼ 7.2% | -14.18M▼ 0.9% | -18.46M▼ 30.2% | -36.87M▼ 99.7% | -88.43M▼ 139.9% | -43M▲ 51.4% | -70.58M▼ 64.1% | -83.25M▼ 18.0% | -86.47M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | 65.58% | -7.16% | -0.88% | -30.18% | -99.66% | -139.86% | 51.37% | -64.13% | -17.96% | - |
EBITDA | -13.1M | -14.05M | -14M | -18.28M | -36.67M | -88.06M | -42.63M | -70.22M | -82.94M | -86.39M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | 65.61% | -7.25% | 0.33% | -30.57% | -100.59% | -140.12% | 51.59% | -64.73% | -18.12% | -11.6% |
D&A (Non-Cash Add-back) | 22K | 11K | 182K | 183K | 195K | 373K | 374K | 359K | 313K | 81K |
EBIT | -13.12M | -14.06M | -16.01M | -16.18M | -36.87M | -39.78M | -43M | -70.58M | -83.25M | -86.47M |
Net Interest Income | 0 | 0 | 0 | -9.66M | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 9.66M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 5K | -5K | -1.83M | -4.75M | 7K | 462K | -73.54M | 34.82M | 37.67M | 8.36M |
Pretax Income | -13.12M▲ 0% | -14.06M▼ 7.2% | -16.01M▼ 13.8% | -23.21M▼ 45.0% | -36.86M▼ 58.8% | -87.97M▼ 138.6% | -116.54M▼ 32.5% | -35.75M▲ 69.3% | -45.58M▼ 27.5% | -78.11M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | -5K | 0 | -404K | -2.35M | 0 | 0 | 431K | 35K | 35K |
Effective Tax Rate % | 0% | 0.04% | 0% | 1.74% | 6.39% | 0% | 0% | -1.21% | -0.08% | -0.04% |
Net Income | -13.12M▲ 0% | -14.06M▼ 7.2% | -16.01M▼ 13.8% | -22.81M▼ 42.5% | -34.51M▼ 51.3% | -87.97M▼ 154.9% | -116.54M▼ 32.5% | -36.18M▲ 69.0% | -45.62M▼ 26.1% | -78.15M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | 65.45% | -7.24% | -13.84% | -42.47% | -51.27% | -154.93% | -32.48% | 68.95% | -26.07% | -310.26% |
Net Income (Continuing) | -13.12M | -14.06M | -16.01M | -22.81M | -34.51M | -87.97M | -116.54M | -36.18M | -45.62M | -78.15M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -41.40▲ 0% | -28.11▲ 32.1% | -24.42▲ 13.1% | -17.16▲ 29.7% | -2.33▲ 86.4% | -6.16▼ 164.4% | -4.73▲ 23.2% | -0.75▲ 84.1% | -0.56▲ 25.3% | -0.70▲ 0% |
EPS Growth % | 89.61% | 32.1% | 13.13% | 29.73% | 86.42% | -164.38% | 23.21% | 84.14% | 25.33% | 60.71% |
EPS (Basic) | -41.40 | -28.11 | -24.42 | -17.16 | -2.33 | -6.16 | -4.73 | -0.75 | -0.56 | - |
Diluted Shares Outstanding | 259.87K | 500.3K | 655.52K | 15.16M | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M | 112.42M |
Basic Shares Outstanding | 259.87K | 500.3K | 655.52K | 15.16M | 14.82M | 14.29M | 24.62M | 48.54M | 81.84M | 112.42M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ELDN Balance Sheet
Eledon Pharmaceuticals, Inc. (ELDN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 19M | 14.28M | 9.97M | 115.63M | 88.35M | 59.52M | 56.13M | 143.73M | 135.69M | 113.57M |
Cash & Short-Term Investments | 17.23M | 12.97M | 8.79M | 114.19M | 84.83M | 56.41M | 51.1M | 140.18M | 133.34M | 111.09M |
Cash Only | 17.23M | 12.97M | 8.79M | 114.19M | 84.83M | 56.41M | 4.61M | 20.55M | 22.81M | 6.15M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 46.49M | 119.63M | 110.53M | 104.94M |
Accounts Receivable | 0 | 594K | 245K | 110K | 0 | 0 | 0 | 0 | 514K | 583K |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 881K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | 1.77K | - | - | - | - | - | - | - |
Other Current Assets | 88K | 36K | 54K | 38K | 34K | 28K | 90K | 729K | 11K | 9K |
Total Non-Current Assets | 1.89M | 2.75M | 960K | 81.56M | 82.2M | 33.27M | 32.94M | 33.67M | 33.32M | 33.09M |
Property, Plant & Equipment | 25K | 14K | 321K | 138K | 768K | 739K | 365K | 926K | 613K | 530K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 1.87M | 1.87M | 0 | 48.65M | 48.65M | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 32.39M | 32.39M | 32.39M | 32.39M | 32.39M | 32.39M | 32.39M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 869K | 639K | 383K | 400K | 150K | 186K | 363K | 322K | 177K |
Total Assets | 20.89M▲ 0% | 17.03M▼ 18.5% | 10.93M▼ 35.8% | 197.19M▲ 1703.9% | 170.55M▼ 13.5% | 92.79M▼ 45.6% | 89.07M▼ 4.0% | 177.41M▲ 99.2% | 169.01M▼ 4.7% | 146.67M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -29.8% | -18.5% | -35.8% | 1703.91% | -13.51% | -45.59% | -4.02% | 99.18% | -4.73% | 19.8% |
Total Current Liabilities | 1.44M | 2.53M | 1.32M | 2.48M | 4.4M | 6.47M | 3.9M | 11.58M | 18.34M | 13.46M |
Accounts Payable | 418K | 689K | 329K | 1.37M | 1.81M | 2.2M | 967K | 5.83M | 3.63M | 6.58M |
Days Payables Outstanding | 6.93K | 22.86K | 659.81 | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 369K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 98K | 1.51M | 0 | 2M | 1.6M | 4.18M | 4.86M |
Current Ratio | 13.19x | 5.63x | 7.54x | 46.57x | 20.07x | 9.19x | 14.41x | 12.42x | 7.40x | 8.44x |
Quick Ratio | 13.19x | 5.63x | 6.88x | 46.57x | 20.07x | 9.19x | 14.41x | 12.42x | 7.40x | 8.44x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 1.02M | 1.84M | 144K | 4.11M | 2.15M | 2.13M | 77.96M | 47.69M | 69.58M | 32.75M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 144K | 0 | 400K | 383K | 0 | 640K | 283K | 1.31M |
Deferred Tax Liabilities | 0 | 0 | 0 | 4.11M | 1.75M | 0 | 1.75M | 2.18M | 2.19M | 8.74M |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 1.75M | 76.21M | 44.87M | 67.11M | 30.38M |
Total Liabilities | 1.44M | 2.53M | 1.47M | 6.59M | 6.55M | 8.61M | 81.86M | 59.27M | 87.92M | 46.21M |
Total Debt | 0 | 0 | 324K | 144K | 769K | 746K | 383K | 954K | 641K | 555K |
Net Debt | -17.23M | -12.97M | -8.47M | -114.05M | -84.06M | -55.66M | -4.23M | -19.59M | -22.17M | -5.6M |
Debt / Equity | - | - | 0.03x | 0.00x | 0.00x | 0.01x | 0.05x | 0.01x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.06x |
Interest Coverage | - | - | - | -1.68x | - | - | - | - | - | - |
Total Equity | 19.45M▲ 0% | 14.49M▼ 25.5% | 9.46M▼ 34.7% | 190.6M▲ 1913.7% | 164M▼ 14.0% | 84.18M▼ 48.7% | 7.21M▼ 91.4% | 118.14M▲ 1539.0% | 81.08M▼ 31.4% | 100.46M▲ 0% |
Equity Growth % | -27.57% | -25.5% | -34.69% | 1913.69% | -13.96% | -48.67% | -91.44% | 1539.01% | -31.37% | 1250.04% |
Book Value per Share | 74.85 | 28.97 | 14.44 | 12.57 | 11.07 | 5.89 | 0.29 | 2.43 | 0.99 | 0.89 |
Total Shareholders' Equity | 19.45M | 14.49M | 9.46M | 190.6M | 164M | 84.18M | 7.21M | 118.14M | 81.08M | 100.46M |
Common Stock | 7K | 9K | 13K | 15K | 14K | 14K | 24K | 60K | 75K | 76K |
Retained Earnings | -27.51M | -41.57M | -57.58M | -80.39M | -114.9M | -202.87M | -319.4M | -355.59M | -401.2M | -440.23M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26K | 24K | -72K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ELDN Cash Flow Statement
Eledon Pharmaceuticals, Inc. (ELDN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -14.94M | -11.89M | -13.86M | -15.21M | -28.91M | -28.42M | -39.53M | -47.27M | -62.34M | -68.89M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | 59.09% | 20.4% | -16.51% | -9.78% | -90.07% | 1.69% | -39.06% | -19.59% | -31.88% | -165.87% |
Net Income | -13.12M | -14.06M | -16.01M | -22.81M | -34.51M | -87.97M | -116.54M | -36.18M | -45.62M | -78.15M |
Depreciation & Amortization | 22K | 11K | 182K | 183K | 195K | 373K | 374K | 359K | 0 | 0 |
Stock-Based Compensation | 579K | 1.54M | 1.31M | 3.17M | 7.9M | 8.15M | 6.54M | 13.12M | 10.45M | 7.59M |
Deferred Taxes | 0 | 0 | 0 | -404K | -2.35M | 0 | 0 | 431K | 5K | 5K |
Other Non-Cash Items | 49K | 471K | 1.87M | 4.83M | 0 | 48.65M | 75.01M | -33.71M | -34.83M | -4.9M |
Working Capital Changes | -2.48M | 618K | -1.2M | -180K | -152K | 2.37M | -4.92M | 8.71M | 7.65M | 6.56M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -1.96M | 1.09M | -1.39M | -39K | 2.14M | 2.08M | -2.6M | 7.75M | 6.72M | 4.83M |
Cash from Investing | 23.26M | 0 | 0 | 11.04M | 0 | 0 | -45.29M | -70.31M | 10.79M | 12.86M |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 23.25M | 0 | 0 | 11.04M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 8K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 7.87M | 7.56M | 9.68M | 109.58M | -449K | 0 | 33.02M | 133.52M | 53.81M | 53.69M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 4.75M | 7.49M | 9.68M | 104.23M | -449K | 0 | 33.02M | 133.31M | 53.81M | 53.58M |
Dividends Paid | 0 | 0 | 0 | -25K | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -25K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 3.12M | 71K | 0 | 5.38M | 0 | 0 | 0 | 215K | 0 | 115K |
Net Change in Cash | 16.19M▲ 0% | -4.33M▼ 126.8% | -4.18M▲ 3.5% | 105.4M▲ 2621.0% | -29.36M▼ 127.9% | -28.42M▲ 3.2% | -51.8M▼ 82.2% | 15.94M▲ 130.8% | 2.26M▼ 85.8% | -2.34M▲ 0% |
Free Cash Flow | -14.94M▲ 0% | -11.89M▲ 20.4% | -13.86M▼ 16.5% | -15.21M▼ 9.8% | -28.91M▼ 90.1% | -28.42M▲ 1.7% | -39.53M▼ 39.1% | -47.27M▼ 19.6% | -62.34M▼ 31.9% | -68.89M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | 59.11% | 20.4% | -16.51% | -9.78% | -90.07% | 1.69% | -39.06% | -19.59% | -31.88% | -26.2% |
FCF per Share | -57.49 | -23.77 | -21.14 | -1.00 | -1.95 | -1.99 | -1.61 | -0.97 | -0.76 | -0.61 |
FCF Conversion (FCF/Net Income) | 1.14x | 0.85x | 0.87x | 0.67x | 0.84x | 0.32x | 0.34x | 1.31x | 1.37x | 0.88x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ELDN Key Ratios
Eledon Pharmaceuticals, Inc. (ELDN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -56.64% | -82.87% | -133.66% | -22.8% | -19.46% | -70.89% | -255.03% | -57.73% | -45.79% | -96.8% |
Return on Invested Capital (ROIC) | -211.61% | -564.05% | -844.96% | -35.72% | -35.34% | -122.31% | -204.77% | -104.28% | -79.31% | -90.3% |
Debt / Equity | - | - | 0.03x | 0.00x | 0.00x | 0.01x | 0.05x | 0.01x | 0.01x | 0.01x |
Interest Coverage | - | - | - | -1.68x | - | - | - | - | - | - |
FCF Conversion | 1.14x | 0.85x | 0.87x | 0.67x | 0.84x | 0.32x | 0.34x | 1.31x | 1.37x | 0.88x |
Related:ELDN Dividend History·ELDN Revenue History·ELDN Price History·ELDN P/E History·ELDN Financial Ratios·ELDN Institutional Holders
ELDN SEC Filings & Documents
Eledon Pharmaceuticals, Inc. (ELDN) SEC filings — annual & quarterly reports (10-K, 10-Q)
ELDN Frequently Asked Questions
Eledon Pharmaceuticals, Inc. (ELDN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Eledon Pharmaceuticals, Inc. (ELDN) grew revenue by 0.0% over the past year. Growth has been modest.
Eledon Pharmaceuticals, Inc. (ELDN) reported a net loss of $78.1M for fiscal year 2025.
Dividend & Returns
Eledon Pharmaceuticals, Inc. (ELDN) has a return on equity (ROE) of -45.8%. Negative ROE indicates the company is unprofitable.
Eledon Pharmaceuticals, Inc. (ELDN) had negative free cash flow of $68.9M in fiscal year 2025, likely due to heavy capital investments.